• Patients with bone metastases have comparably poorer survival in response to immune checkpoint inhibitors (ICIs) compared to patients without bone metastases. • Co-administration of ICIs with bone-targeted agents improve outcomes in patients with bone metastasis. • Fracture risk is elevated in patients treated with ICIs, regardless of whether they have bone metastatic disease. • There are limited pre-clinical studies investigating osteoimmunology in the tumor-bone microenvironment, but myeloid cells and CD4+ and especially CD8+ T cells are likely to play a role in bone metastatic progression.